Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis.

Trial Profile

Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Spondylarthritis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 16 Nov 2011 New source identified and integrated (European Clinical Trials Database).
    • 16 Nov 2011 Actual initiation date 21 Apr 2011 added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top